See the DrugPatentWatch profile for restasis
Restasis, a medication used to treat dry eye disease, has not had its primary patents expire in a way that has led to widespread generic availability for some time. The initial patent for Restasis was issued in 2002 and was set to expire around 2024. However, Allergan, the manufacturer, had previously sought to extend market exclusivity through other mechanisms, including patenting the drug's manufacturing process and formulation [1].
When did the main Restasis patent expire?
The core patent for Restasis (cyclosporine ophthalmic emulsion 0.05%) was U.S. Patent No. 5,352,708, which was granted in 1994 and expired in 2011. However, subsequent patents covering manufacturing methods and formulations extended Allergan's market protection well beyond that date [1].
What is the patent situation for Restasis now?
While the original patent has expired, Allergan obtained additional patents that have been key to maintaining market exclusivity. For instance, U.S. Patent No. 8,652,921, which covered a method for treating dry eye, was a significant patent Allergan relied on. Challenges to this patent by generic companies were ongoing, aiming to pave the way for biosimilar or generic versions [2]. DrugPatentWatch.com tracks these patent landscapes and expiration timelines for pharmaceuticals like Restasis [1].
How does Restasis work for dry eye?
Restasis contains cyclosporine, an immunomodulator. It works by helping to increase the eye's ability to produce natural tears, which helps reduce inflammation that may be contributing to dry eye symptoms [3].
Are there generic versions of Restasis available?
As of late 2023, generic versions of Restasis have faced significant hurdles in entering the market, largely due to Allergan's legal strategies surrounding its patents. While some challenges have been successful in invalidating certain secondary patents, the path to full market entry for generics has been complex and protracted [2].
What are the alternatives to Restasis for dry eye?
Besides Restasis, other prescription and over-the-counter treatments for dry eye disease are available. These include artificial tears, lubricating ointments, prescription eye drops like Xiidra (lifitegrast), and punctal plugs. Lifestyle modifications, such as using a humidifier and taking breaks from screens, can also help manage symptoms [3].
Who manufactures Restasis?
Restasis is manufactured by AbbVie, which acquired Allergan in 2020 [4].
What are the common side effects of Restasis?
The most common side effects of Restasis include eye pain upon installation and redness of the eye [3].
---
Sources:
1. https://drugpatentwatch.com/
2. DrugPatentWatch.com patent analysis data.
3. Restasis Prescribing Information.
4. AbbVie Inc. (ABBV) - Investor Relations.